Home
ALVOW
ALVOW News

Latest Alvotech Warrant (ALVOW) News on November 17, 2024

Alvotech Third Quarter 2024 Earnings: US$0.041 loss per share (vs US$0.81 loss in 3Q 2023)

Simply Wall St.

a day ago

Alvotech Third Quarter 2024 Earnings: US$0.041 loss per share (vs US$0.81 loss in 3Q 2023)

GuruFocus.com

3 days ago

Alvotech (ALVO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Advancements

Alvotech Reports Financial Results for the First Nine Months of 2024

GlobeNewswire

4 days ago

Alvotech Reports Financial Results for the First Nine Months of 2024

Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024

GlobeNewswire

10 days ago

Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024

European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)

GlobeNewswire

13 days ago

European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)

Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET

GlobeNewswire

18 days ago

Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET

Exploring High Growth Tech Stocks In The US October 2024

Simply Wall St.

20 days ago

Exploring High Growth Tech Stocks In The US October 2024

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024

GlobeNewswire

23 days ago

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024

GlobeNewswire

23 days ago

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

GlobeNewswire

a month ago

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

GlobeNewswire

a month ago

European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

High Growth Tech Stocks in the United States to Watch

Simply Wall St.

2 months ago

High Growth Tech Stocks in the United States to Watch

Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®

GlobeNewswire

2 months ago

Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®

Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

GlobeNewswire

3 months ago

Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Alvotech Second Quarter 2024 Earnings: EPS: US$0.25 (vs US$0.83 in 2Q 2023)

Simply Wall St.

3 months ago

Alvotech Second Quarter 2024 Earnings: EPS: US$0.25 (vs US$0.83 in 2Q 2023)

Alvotech's (NASDAQ:ALVO) biggest owners are private equity firms who got richer after stock soared 19% last week

Simply Wall St.

3 months ago

Alvotech's (NASDAQ:ALVO) biggest owners are private equity firms who got richer after stock soared 19% last week

Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024

GlobeNewswire

3 months ago

Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024

European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

GlobeNewswire

3 months ago

European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET

GlobeNewswire

4 months ago

Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET

STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe

GlobeNewswire

4 months ago

STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe

Alvotech Announces Closing of Private Debt Financing

GlobeNewswire

4 months ago

Alvotech Announces Closing of Private Debt Financing

Alvotech Announces Closing of Private Debt Financing

GlobeNewswire

4 months ago

Alvotech Announces Closing of Private Debt Financing

Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

GlobeNewswire

5 months ago

Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

Alvotech Issues New Shares to Holders of Convertible Bonds

GlobeNewswire

5 months ago

Alvotech Issues New Shares to Holders of Convertible Bonds

Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024

GlobeNewswire

5 months ago

Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024

Alvotech Receives Conversion Notices for Majority of Convertible Bonds

GlobeNewswire

5 months ago

Alvotech Receives Conversion Notices for Majority of Convertible Bonds

Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe

GlobeNewswire

5 months ago

Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe

Alvotech and STADA add to Strategic Alliance through Denosumab Partnership

GlobeNewswire

5 months ago

Alvotech and STADA add to Strategic Alliance through Denosumab Partnership

Alvotech Announces Strategic Refinancing Agreement

GlobeNewswire

5 months ago

Alvotech Announces Strategic Refinancing Agreement

Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024

GlobeNewswire

6 months ago

Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024

Brokers Are Upgrading Their Views On Alvotech (NASDAQ:ALVO) With These New Forecasts

Simply Wall St.

6 months ago

Brokers Are Upgrading Their Views On Alvotech (NASDAQ:ALVO) With These New Forecasts

Alvotech First Quarter 2024 Earnings: US$0.89 loss per share (vs US$1.24 loss in 1Q 2023)

Simply Wall St.

6 months ago

Alvotech First Quarter 2024 Earnings: US$0.89 loss per share (vs US$1.24 loss in 1Q 2023)

Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update

GlobeNewswire

6 months ago

Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update

Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK

Business Wire

6 months ago

Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

Business Wire

6 months ago

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

Alvotech S.A. Annual General Meeting to be held June 7, 2024

GlobeNewswire

6 months ago

Alvotech S.A. Annual General Meeting to be held June 7, 2024

Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)

GlobeNewswire

6 months ago

Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)

Alvotech Announces Participation at BofA Securities Healthcare Conference 2024

GlobeNewswire

7 months ago

Alvotech Announces Participation at BofA Securities Healthcare Conference 2024

Alvotech Announces Participation at BofA Securities Healthcare Conference 2024

GlobeNewswire

7 months ago

Alvotech Announces Participation at BofA Securities Healthcare Conference 2024

U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)

GlobeNewswire

7 months ago

U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)

U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)

GlobeNewswire

7 months ago

U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)

Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)

GlobeNewswire

7 months ago

Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)

GlobeNewswire

7 months ago

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

Business Wire

7 months ago

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024

GlobeNewswire

7 months ago

Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024

Alvotech Announces Increase in Number of Own Shares

GlobeNewswire

8 months ago

Alvotech Announces Increase in Number of Own Shares

Analysts Expect Breakeven For Alvotech (NASDAQ:ALVO) Before Long

Simply Wall St.

8 months ago

Analysts Expect Breakeven For Alvotech (NASDAQ:ALVO) Before Long

Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update

GlobeNewswire

8 months ago

Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update

Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET

GlobeNewswire

8 months ago

Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET

Alvotech Appoints Interim Chief Quality Officer

GlobeNewswire

9 months ago

Alvotech Appoints Interim Chief Quality Officer

Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share

GlobeNewswire

9 months ago

Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share

Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share

GlobeNewswire

9 months ago

Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

GlobeNewswire

9 months ago

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

Business Wire

9 months ago

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)

GlobeNewswire

9 months ago

Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)

Is Alvotech (NASDAQ:ALVO) Trading At A 48% Discount?

Simply Wall St.

9 months ago

Is Alvotech (NASDAQ:ALVO) Trading At A 48% Discount?

Reuters

9 months ago

UPDATE 1-Brazil's military reinforces border with Venezuela and Guyana due to Esequibo

Microsoft, Tesla, Netflix, and More: Big Names in the Market Worth Talking About

Motley Fool

9 months ago

Microsoft, Tesla, Netflix, and More: Big Names in the Market Worth Talking About

Is There Any Hope for Cassava Sciences Stock?

Motley Fool

9 months ago

Is There Any Hope for Cassava Sciences Stock?

Brinker International, Inc. (NYSE:EAT) Q2 2024 Earnings Call Transcript

Insider Monkey

10 months ago

Brinker International, Inc. (NYSE:EAT) Q2 2024 Earnings Call Transcript

Idaho Milk Products Celebrates Pranav Vashisht’s Best Paper Award at International Conference

GlobeNewswire

10 months ago

Idaho Milk Products Celebrates Pranav Vashisht’s Best Paper Award at International Conference

Ireland celebrates its 'Matron Saint' St. Brigid on the 1500th anniversary of her passing

CNW Group

10 months ago

Ireland celebrates its 'Matron Saint' St. Brigid on the 1500th anniversary of her passing

7/2024・Trifork adjusts outlook for 2023 financial results and reports strong performance in Trifork Labs

GlobeNewswire

10 months ago

7/2024・Trifork adjusts outlook for 2023 financial results and reports strong performance in Trifork Labs

Google starts a limited test of generative AI tools in Maps

Engadget

10 months ago

Google starts a limited test of generative AI tools in Maps

Dave Ramsey: 10 Genius Things To Do With Your Money

GOBankingRates

10 months ago

Dave Ramsey: 10 Genius Things To Do With Your Money

Northline Seafoods Streamlines Processes From Catch to Customer With the Help of NorthScope ERP Software

ACCESSWIRE

10 months ago

Northline Seafoods Streamlines Processes From Catch to Customer With the Help of NorthScope ERP Software

Traefik Labs Appoints Sudeep Goswami as CEO, Founder Emile Vauge Transitions to Chief Technology Officer

Business Wire

10 months ago

Traefik Labs Appoints Sudeep Goswami as CEO, Founder Emile Vauge Transitions to Chief Technology Officer

OKI Group Obtains SBT Certification for Greenhouse Gas Emission Reduction Targets

Business Wire

10 months ago

OKI Group Obtains SBT Certification for Greenhouse Gas Emission Reduction Targets

CoStar Group to Report Financial Results for Fourth Quarter and Full Year 2023 on February 20, 2024

Business Wire

10 months ago

CoStar Group to Report Financial Results for Fourth Quarter and Full Year 2023 on February 20, 2024

Esker Named in First-Ever Gartner® Magic Quadrant™ for Source-to-Pay Suites

Business Wire

10 months ago

Esker Named in First-Ever Gartner® Magic Quadrant™ for Source-to-Pay Suites

Mortgage Rates Tick Down

GlobeNewswire

10 months ago

Mortgage Rates Tick Down

Old Dominion Freight Line, Inc. (NASDAQ:ODFL) Q4 2023 Earnings Call Transcript

Insider Monkey

10 months ago

Old Dominion Freight Line, Inc. (NASDAQ:ODFL) Q4 2023 Earnings Call Transcript

Media layoffs: Google, Paramount, Disney, and others commit to job cuts in 2024

Yahoo Finance

10 months ago

Media layoffs: Google, Paramount, Disney, and others commit to job cuts in 2024

Airspace Link FAA-Approved to Provide B4UFLY Services: Streamlining the Safe Integration of Drones into the National Airspace

PR Newswire

10 months ago

Airspace Link FAA-Approved to Provide B4UFLY Services: Streamlining the Safe Integration of Drones into the National Airspace

Chapel Hart Kicks Off Ford Truck Month with "This Girl Likes Fords"

Business Wire

10 months ago

Chapel Hart Kicks Off Ford Truck Month with "This Girl Likes Fords"

Novartis AG (NYSE:NVS) Q4 2023 Earnings Call Transcript

Insider Monkey

10 months ago

Novartis AG (NYSE:NVS) Q4 2023 Earnings Call Transcript

Can Royal Caribbean Stock Double Again in 2024?

Motley Fool

10 months ago

Can Royal Caribbean Stock Double Again in 2024?

The Leaders Group sponsors NAIFA’s national events and NAIFA-Colorado

GlobeNewswire

10 months ago

The Leaders Group sponsors NAIFA’s national events and NAIFA-Colorado

GCM Grosvenor to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Investor Conference Call on February 13, 2024

GlobeNewswire

10 months ago

GCM Grosvenor to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Investor Conference Call on February 13, 2024

CareMax Announces 1-for-30 Reverse Stock Split

Business Wire

10 months ago

CareMax Announces 1-for-30 Reverse Stock Split

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

GlobeNewswire

10 months ago

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

Whether or not the Fed cuts rates is not the right question

Yahoo Finance

10 months ago

Whether or not the Fed cuts rates is not the right question

Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought Last Week

Motley Fool

10 months ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought Last Week

Holding by top Deutsche Bank investor drops to 0.92% from 3.18% - filing

Reuters

10 months ago

Holding by top Deutsche Bank investor drops to 0.92% from 3.18% - filing

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

Zacks

10 months ago

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

Reuters

10 months ago

UPDATE 1-Brazil's Lula slams miner Vale over 2019 Brumadinho disaster

GlobeNewswire

10 months ago

Optical Brighteners Market to Hit US$ 2,656.2 Million by 2033 | Updated Insights Report by Persistence Market Research

GlobeNewswire

10 months ago

Irradiation Sterilization Services Market anticipated to grow at CAGR of 9.2% by 2030, According to Persistence Market Research

Q-Gold Comments on Trading Activity at Request of the Canadian Investment Regulatory Organization (“CIRO”)

GlobeNewswire

10 months ago

Q-Gold Comments on Trading Activity at Request of the Canadian Investment Regulatory Organization (“CIRO”)

Manufacturing Activity in Central U.S. Drops Sharply at Start of Year

Barrons.com

10 months ago

Manufacturing Activity in Central U.S. Drops Sharply at Start of Year

GlobeNewswire

10 months ago

Automatic Self-cleaning Cat Litter Box Market to Hit US$ 1,262.7 Million by 2030 | Updated Insights Report by Persistence Market Research

Global Automated Parking System (APS) Market Set to Reach $6.6 Billion by 2030: Surging Demand for Space-Efficient and Technologically Advanced Vehicle Storage Solutions

GlobeNewswire

10 months ago

Global Automated Parking System (APS) Market Set to Reach $6.6 Billion by 2030: Surging Demand for Space-Efficient and Technologically Advanced Vehicle Storage Solutions

GlobeNewswire

10 months ago

Viscosupplementation Market Predicted to Hit US$ 13.6 Billion in 2032, Riding on a Strong 10.8% CAGR | According to Persistence Market Research

Deutsche Bank (DB) Earnings Expected to Grow: Should You Buy?

Zacks

10 months ago

Deutsche Bank (DB) Earnings Expected to Grow: Should You Buy?

Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January

InvestorPlace

10 months ago

Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January

Zacks.com featured highlights General Motors, Cemex, Centene, Qifu Technology and Deutsche Bank

Zacks

10 months ago

Zacks.com featured highlights General Motors, Cemex, Centene, Qifu Technology and Deutsche Bank

Where Will CRISPR Therapeutics Be in 5 Years?

Motley Fool

10 months ago

Where Will CRISPR Therapeutics Be in 5 Years?

Thomson Reuters StreetEvents

10 months ago

Q4 2023 AGNC Investment Corp Earnings Call

Zacks

10 months ago

Cannabis ETFs: What's Behind the Latest Surge

AGNC Investment (AGNC) Tops on Q4 Net Spread and Dollar Roll

Zacks

10 months ago

AGNC Investment (AGNC) Tops on Q4 Net Spread and Dollar Roll

Share on Social Networks: